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Skeletal muscleAlthough aberrant miRNA signatures are associated with diabetes, yet, the status and role of altered miRNAs
in the diabetic skeletal muscle is currently poorly understood. Here, we report that 41 miRNAs are altered in
the diabetic gastrocnemius skeletal muscle and of these, miR-135a that is identiﬁed as a critical regulator of
myogenesis, is signiﬁcantly up-regulated. IRS2 is predicted as its potential putative target and its levels are
down-regulated in the diabetic gastrocnemius skeletal muscle. In C2C12 cells, while miR-135a levels de-
creased during differentiation, IRS2 levels were up-regulated. miR-135a signiﬁcantly reduced IRS2 protein
levels and its 3′UTR luciferase reporter activity and these were blunted by the miR-135a inhibitor and muta-
tion in the miR-135a binding site. Knock-down of endogenous miR-135a levels increased IRS2 at the mRNA
and protein levels. miR-135a also attenuated insulin stimulated phosphorylation and activation of PI3Kp85α
and Akt and glucose uptake. miR-135a levels were also found to be elevated in the human diabetic skeletal
muscle. In-vivo silencing of miR-135a alleviated hyperglycemia, improved glucose tolerance and signiﬁcantly
restored the levels of IRS2 and p-Akt in the gastrocnemius skeletal muscle of db/db mice without any effect
on their hepatic levels. These suggest that miR-135a targets IRS2 levels by binding to its 3′UTR and this
interaction regulates skeletal muscle insulin signaling.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of small (~22 nucleotides) non-
coding RNA species that act by regulating the expression of their tar-
get genes by either mRNA degradation or translational repression [1].
Since their discovery in Caenorhabditis elegans [2], miRNAs are now
believed to participate in diverse physiological cellular pathways. In
addition to being involved in cellular phenomena like differentiation,
proliferation and cell signaling [3], miRNAs are also being increasingly
implicated in several pathological states [4].
Type 2 diabetes (T2D) is a complex multi-factorial disease that
sets in due to decreased responsiveness of the peripheral target tis-
sues to insulin (insulin resistance). The resulting hyperglycemia trig-
gers the pancreatic β-cells that initially try to rescue this state by
increasing insulin synthesis and secretion. But when the insulin resis-
tant condition and hyperglycemia persist, these lead to pancreatic
β-cell toxicity and cell death. Of the insulin target tissues, skeletal
muscle insulin resistance is believed to be an early event during the
onset and progression to diabetes [5]. Almost 80% of insulin stimulat-
ed glucose disposal occurs in the skeletal muscle [6,7] and therefore,1 11 27667602x135; fax: +91
l rights reserved.this tissue getting insulin resistant contributes to the pathogenesis
of the overall insulin resistant state. Skeletal muscle glucose uptake
is regulated by the metabolic pathways of glycolysis (~90% of which
corresponds to glucose oxidation) and glycogen synthesis [8].
Skeletal muscle insulin resistance that primarily involves the gly-
cogen synthetic machinery [9,10] is the earliest visible metabolic de-
fect during the onset of the disease [11,12]. Additionally, skeletal
muscle insulin resistance also promotes atherogenic dyslipidemia
and contributes to the development of other deregulations associated
with the metabolic syndrome [13]. Therefore, by virtue of it being the
most important tissue involved in whole body glucose homeostasis
[14], it is imperative that the mechanisms involved in skeletal muscle
insulin resistance are studied in detail.
Diverse mechanisms have been identiﬁed as underlying factors re-
sponsible for skeletal muscle insulin resistance. The emergence of
miRNAs as critical metabolic regulators has added another mechanis-
tic layer of regulation and suggests a possible role of these RNA spe-
cies in this defect of the skeletal muscle. Several reports describe
altered miRNome signatures during diabetes [15–19] and these,
together with other studies that describe the contribution of very
speciﬁc miRNAs in diverse metabolic processes linked to T2D [4], sug-
gest that miRNAs play crucial roles during the onset and progression
of this complex metabolic disease. However, despite the skeletal mus-
cle being a critical contributing tissue in diabetes, very few studies
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[15–17]. In a recent study, miRNA proﬁling in the skeletal muscle of
control and diabetic subjects was studied and 29 miRNAs were
up-regulated and 33 were down-regulated [15]. Of these, miRNAs
that depict skeletal muscle speciﬁc expression were preferentially
down-regulated suggesting that an altered miRNA signature might
have relevance in the diabetic skeletal muscle. In a diabetic GK rat
model, 7 miRNAs were down-regulated and 2 were up-regulated in
the skeletal muscle [16]. miR-24 was one of the up-regulated miRNAs
and its target, p38MAPK was markedly down-regulated suggesting
that these events might contribute to the altered physiology of the di-
abetic skeletal muscle. Apart from these few reports, the signiﬁcance
and role of miRNAs in the skeletal muscle during diabetes has not
been studied enough. Therefore, there is a need for detailed analysis
of miRNAs in the diabetic skeletal muscle so that a comprehensive
role of these small RNA species in this tissue during diabetes could
be unraveled.
In the present study, we report an altered miRNA signature in the
gastrocnemius skeletal muscle of db/db mice. These mice are believed
to exhibit a pattern of diabetes progression that is strikingly similar to
that in humans [20]. Our data show that 41 miRNAs are differentially
regulated; of which 10 and 31 miRNAs were signiﬁcantly up- and
down-regulated, respectively. One of the key altered miRNAs was
miR-135a. miR-135a has been shown to be critical in myogenesis by
targeting the speciﬁc transcription factor, myocyte enhancer factor
2C (MEF2C) [21] and its levels are up-regulated in the degenerative
phase of muscle damage [22]. In this study, we sought to evaluate
the consequence of elevated miR-135a levels in the diabetic gastroc-
nemius skeletal muscle. Our results show that miR-135a targets IRS2
and consequently abrogates insulin signaling and glucose uptake in
skeletal muscle cells that is a critical factor towards initiation of the
diabetic phenotype. This was substantiated by the observation of sig-
niﬁcant alleviation of hyperglycemia and improvement of glucose tol-
erance by in-vivo silencing of miR-135a in db/db mice.
2. Materials and methods
2.1. Animals
Twelve week old male normal (C57BL/KsJ-leprdb/+) and diabetic
(C57BL/KsJ leprdb/leprdb) mice were obtained from the Animal
House Facility of the CSIR-Central Drug Research Institute, Lucknow,
India. The handling and maintenance of these animals (n = 4 from
each group) have been described in a recent report from our labora-
tory [18]. The gastrocnemius skeletal muscles were dissected and
collected in RNA later and stored at −80 °C until further use in all
subsequent experiments that were carried out at the CSIR-Institute
of Genomics and Integrative Biology, Delhi, India. All procedures
were carried out in accordance with the guidelines of the Institutional
Animal Ethical Committee and all experiments were approved by the
same.
2.2. RNA extraction and miRNA microarray
Total RNA from the gastrocnemius skeletal muscle (n = 4) was
extracted using Trizol (Invitrogen, Carlsbad, CA, USA) following the
manufacturer's protocol and quantiﬁed with a NanoDrop spectropho-
tometer (ND-1000, NanoDrop Technologies, DE, USA). Ratios of OD
260/280 were between 1.9 and 2.0. The integrity of RNA samples
was determined in a Bioanalyzer 2100 (Agilent, CA, USA) and all sam-
ples had RIN values in the range of 8.0–8.5.
Microarray experiments for four animals in each group were
carried out with the mouse miRNA 8 × 15K array from Agilent by
Genotypic Technology Pvt. Ltd. Bangalore, India. Total RNA (100 ng)
was de-phosphorylated and the subsequent denaturation, ligation and
hybridization steps were performed according to the manufacturer'sinstructions. Slides were scanned on a microarray scanner (G2565BA,
Agilent) at 100 and 5%XDR settings. Agilent Feature Extraction software
(v9.3.5) was used to extract the raw data. All experiments were
according to the MIAME guidelines and the data that were analyzed
by the method as described below have been deposited to the GEO da-
tabase. The GEO accession number for the same is GSE32376.
2.3. Target prediction and pathway analysis
Predicted targets of miR-135a as extracted from miRanda (http://
www.microRNA.org/), Target Scan (http://www.targetscan.org/) and
PicTar (http://www.PicTar.org/) were used to identify the potential
putative targets of this miRNA. The common targets predicted by all
the three tools were analyzed for the cellular pathways that they en-
rich in using DAVID and KEGG mapping databases that categorize a
set of genes from an input genes' list on the basis of annotation sim-
ilarity and then map them as signiﬁcantly over-represented in a bio-
logical pathway. These suggest that the enriched pathway might play
a role in the physiological condition being considered.
2.4. Cloning and mutagenesis
The IRS2 3′UTR was ampliﬁed using sequence speciﬁc primers
ﬂanking the miR-135a binding site (sense: 5′ CCGCTCGAGGTACCC
TGGGAGGAGGTGAT 3′ and antisense: 5′ ATAAGAATGCGGCCGCTT
TCAACATGGCGGCGATG3′). The PCR product was cloned downstream
of the renilla luciferase gene within the psiCHECK™-2 reporter vector
(Promega, MA, USA) according to the manufacturer's protocol. This
vector harbors an intraplasmid ﬁreﬂy luciferase cassette that is used
as the normalization reporter control. Mutation in the miR-135a
binding site (GCCA → TCTA) in the IRS2 3′UTR was generated with
mutation primers (sense:5′ CCAGCCCCATCGCCTCTATGTTGAAAGCG
GC 3′ and antisense: 5′ GCCGCTTTCAACATAGAGGCGATGGGGCTGG
3′) (under-lined regions depict the mutated sites) using the
Quickchange XL site-directed mutagenesis kit (Stratagene, CA, USA).
Presence of the inserts and incorporation of the mutation were con-
ﬁrmed by sequencing.
2.5. Cell culture
The C2C12 mouse myoblast cell line was obtained from the
National Center for Cell Science (NCCS), Pune, India. Cells were main-
tained in Dulbecco'smodiﬁed Eagle'smedium (DMEM) supplemented
with 10%fetal bovine serum and 10 units/ml penicillin/streptomycin/
glutamine. At a conﬂuence of 70–80%, the medium was replaced
with DMEM supplemented with 0.5% fetal bovine serum (differentia-
tion medium) and 10units/ml penicillin/streptomycin/glutamine to
promote myoblast differentiation into myotubes that were evident
after four days of incubation.
2.6. Quantitative real-time PCR (qRT-PCR) analyses
miR-135a levels were assessed in mice gastrocnemius skeletal tis-
sues (normal and diabetic) and C2C12 cells (undifferentiated and dif-
ferentiated) using SYBR Green (Applied Biosystems, CA, USA) and
miRNA speciﬁc primers (Forward Primer: 5′ACACTCCAGCTGGGTATG
GCTTTTTATTCCT3′ and universal Reverse primer: 5′GGTGTCGTGGA
GTCGGCAA3′). RNA (2 μg) from the skeletal tissues was reverse
transcribed using the speciﬁc miR-135a stem-loop RT primer (5′
CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCACATAG3′) and
then subjected to quantitative PCR with SYBR Green. The speciﬁcity
of the ampliﬁed products was assessed by the dissociation curve anal-
ysis in an ABI PRISM 7500 thermal cycler. Data was analyzed using
the Pfafﬂ method [23] and normalized to U6 snRNA. Reactions from
each animal (n = 4) of both groups were run in triplicate. For quan-
titation of miR-135a levels in C2C12 cells, total RNA (2 μg) from
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scribed and subjected to RT-PCR as described above. All experiments
were done in triplicate and normalized to U6 snRNA.
2.7. Transfection of miR-135a
Differentiated C2C12 cells were transfected with the scramble
or miR-135a mimic (25–100 nM) and miR-135a inhibitor (50 nM)
(Dharmacon, Lafayette Colorado, USA) using Lipofectamine 2000
(Invitrogen, CA, USA). The inhibitor used is a non-hydrolysable
single-stranded reverse complement of miR-135a with ﬂanking hair-
pin structures and it acts by irreversible binding to the mature form of
miR-135a and thereby preventing its binding to the target. After 48 h,
cells were harvested and subjected to RT-PCR and Western Blot anal-
yses as described below.
2.8. Quantitative real time-PCR (qRT-PCR) for IRS2 and Western Blot
analyses
The levels of IRS2 at the protein level were assessed by Western
Blot in cells transfected with the miR-135a mimic and its inhibitor.
50 μg protein of each incubation was resolved on SDS-PAGE, trans-
ferred to nitrocellulose membranes and IRS2 levels were detected
with anti-IRS2 antibody. Endogenous miR-135a levels were knocked
down by transfecting miR-135a inhibitors (50 and 100 nM) and on
termination of incubation (48 h), the levels of IRS2 (at the mRNA
and protein level) were determined. For IRS2 mRNA levels, 2 μg of
total RNA was reverse transcribed and the levels of IRS2 mRNA
were determined by quantitative RT-PCR using gene-speciﬁc primers
(sense: 5′ CTGCGTCCTCTCCCAAAGTG 3′ and antisense: 5′ GGGGT
CATGGGCATGTAGC 3′). 18S rRNA and β-actin were taken as the load-
ing controls for qRT-PCR and Western Blot analyses, respectively. To
study the effect of miR-135a on insulin signaling, cells were
transfected with miR-135a (100 nM) and/or its inhibitor and after
48 h, cells were incubated with or without insulin (100 nM) for
20 min, pelleted down, lysed in cell lysis buffer (Sigma, St. Louis,
USA) and lysates were centrifuged at 15,000 g for 15 min. 50 μg pro-
tein (supernatant) of each incubation was resolved on SDS-PAGE,
transferred to nitrocellulose membranes and probed with Akt,
p-Akt, PI3Kp85α (Santa Cruz, CA, USA) and p-PI3Kp85α (Cell Signal-
ing, MA, USA) antibodies. Immuno-reactive bands were detected by
BCIP-NBT. β-actin (Santa Cruz) was taken as the loading control.
The mRNA and protein levels of IRS2 in normal and diabetic (db/db)
mice gastrocnemius skeletal muscle was also detected in an identical
manner.
2.9. Luciferase activity assay
For the luciferase assay to validate IRS2 as a target of miR-135a,
HEK cells (approximately 75,000 cells) were seeded in 12-well plates
and used for the experiment. HEK cells were chosen because they
express low levels of miR-135a [24]. Cells were transfected with
either the scramble or various doses of the miR-135a mimic
(5–50 nM). 150 ng of the wild type (psiCHECK2-IRS2-UTR) or mu-
tant (psiCHECK2-IRS2-UTR-mut) IRS2 3′UTR or the vector alone
were co-transfected using Lipofectamine 2000 according to the
manufacturer's instructions. After 48 h, cells were lysed and ﬁreﬂy
and Renilla luciferase activities were measured using the dual-
luciferase reporter assay kit (Promega, MA, USA) on a luminometer
(Orion II, Luminometer, Germany). To check the speciﬁcity of the
miR-135a effect, HEK cells were co-transfected with psiCHECK2-IRS2-3′
UTR (150 ng wild type or mutant) and miR-135a mimic (25 nM) and
its inhibitor (10 nM) and the luciferase activities weremeasured. Control
cells were transfected with the scramble sequence. Renilla reporter lucif-
erase activity was normalized to ﬁreﬂy luciferase activity.2.10. 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxy-D-
glucose (2-NBDG) uptake assay
The effect of miR-135a and its inhibitor on insulin stimulated glu-
cose uptake was assessed by 2-NBDG uptake. Differentiated C2C12
cells were transfected with miR-135a and its inhibitor as described
above. After 48 h, cells were pre-incubated in 0.05% glucose con-
taining Krebs Ringer Bicarbonate buffer (pH 7.4 with 2%BSA). After
this pre-incubation at 37 °C for 30 min, cells were incubated in the
presence or absence of insulin (100 nM) for 10 min and then further
treated with insulin and 500 μM of 2-NBDG (Invitrogen, CA, USA)
for 2 h at 37 °C in glucose-free Krebs Ringer Bicarbonate buffer
containing 2% BSA. On termination of incubation, the cells were
washed with cold phosphate-buffered saline (PBS) and 2-NBDG up-
take into the cells was assayed by FACS analysis (BD Biosciences,
USA). Results are expressed as Fluorescence Intensity (arbitrary
units) of the various treatments with respect to the control.
2.11. Microarray data analysis
Raw data was extracted using the Agilent Feature Extraction soft-
ware (V9.3.5) and was normalized using quantile normalization in the
R language (version 2.14.0, http://www.r-project.org/ ). Values were
then log2 transformed and median centered across miRNAs and sam-
ples. Z-score statistical test was applied to the normalized data and
miRNAs having a Z-score less than or equal to −1.96 (that is inferred
as a signiﬁcance of p b 0.05) were considered as down-regulated and
those greater than or equal to +1.96, as up-regulated miRNAs.
2.12. miR-135a levels in the normal and diabetic human skeletal muscle
Total RNA from age (65–75 years) and sex matched (male) normal
and type 2 diabetic human skeletal muscle (n = 3 each) were pur-
chased from M/S. Biochain Life Sciences (Newark, CA, USA). All tissues
were collected byM/S. Biochainwith informed consent from the donors
and their relatives and according to the approval of M/S. Biochain's
Regulatory Board. The glucose levels of the normal individuals were
4.7 ± 2.02 mM and those of the diabetic individuals were 12.59 ±
1.15 mM. Total RNA (2 μg) of each individual was reverse transcribed
and quantiﬁed for miR-135a levels using Real-Time PCR as described
above in a StepOne Plus RT-PCR system (Applied Biosystems, CA,
USA). U6 snRNA was used for normalization. RNA from each individual
was run in triplicate and data were analyzed as described above.
2.13. In-vivo studies with miR-135a antagomir
To validate if miR-135a inhibition could normalize the diabetic sta-
tus in vivo, experiments were done in the normal and diabetic db/db
mice. Animals (n = 5 in each group) were divided into three groups:
normal db/+mice injectedwith scramble; diabetic db/dbmice injected
with scramble and db/db mice injected with antagomir-135a. Chemi-
cally modiﬁed HPLC puriﬁed miR-135a antagomirs (5′ C⁎A⁎CAUAGGA
AUAAAAA GCC⁎A⁎U⁎A⁎-chol3′ where all bases were 2-O′methyl
modiﬁed phosphoramidites, “*” represents phosphorothioate linkages,
and “-Chol” refers to cholesterol moiety) and scramble (5′ G⁎A⁎CUC
CACUCUUCUAGAAU⁎A⁎A⁎C⁎-chol3′) with the same modiﬁcations
were synthesized and purchased from Dharmacon (Lafayette, CO,
USA). All oligos (antagomir or scramble) were dissolved in saline and
injected through the tail vein (100 μl) for three consecutive days at a
dose of 80 mg/kg body weight [25]. Random blood glucose levels of
fed animals were measured at the start of the experiment (day 0) and
on each day of the three consecutive days of the experiment
(ACCU-CHEK, Roche). After 24 h of the last injection i.e. on the fourth
day, oral glucose tolerance test (OGTT) was performed after an over-
night fasting period. All animals were given an oral dose of glucose at
a dose of 3 g/kg body weight and the blood glucose levels were
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next day and the gastrocnemius skeletal muscle and liver tissues were
dissected and the levels of IRS2, p-Akt and Akt were determined by
Western Blot as described above.
2.14. Densitometry analysis
Protein expression was evaluated by densitometric analysis
performed with Alpha DigiDoc 1201 software (Alpha Innotech Corpo-
ration, CA, USA). The same size rectangle box was drawn surrounding
each band and the intensity of each was analyzed by the program
after subtraction of the background intensity.
2.15. Statistical analysis
All experiments were done thrice and data are expressed as
means ± SEM. Values represent the means of at least three indepen-
dent experiments. The statistical signiﬁcance of differences was
evaluated with the Student's t-test and p-values of at least b0.05
are considered statistically signiﬁcant.
3. Results
3.1. miR-135a levels are up-regulated in the gastrocnemius skeletal
muscle of db/db mice
To evaluate miRNA expression signatures in the gastrocnemius
skeletal muscle of db/db mice, we performed a miRNA microarrayFig. 1. Levels of miR-135a in normal and diabetic mice skeletal muscle and the pathways th
muscle that were identiﬁed by miRNA microarray. The fold change of the individual miRNAs
was done with tissues from four animals each of the normal and diabetic group. (B) Targets t
the miRNAs that are predicted to have targets in one or more algorithms are shown. (C) Com
pathways they enrich in using DAVID and KEGG mapping databases and the signiﬁcant (p b
miR-135a in the skeletal muscle of normal (db/+) and diabetic (db/db) mice as evaluated
tissue were reverse transcribed and subjected to quantitative Real-Time PCR as described in
iments from each animal. ***p b 0.001 as compared to normal (non-diabetic) mice.using the miRNA mouse array from Agilent Technologies (CA, USA).
Gastrocnemius skeletal muscle tissues of four animals each from the
normal (db/+) and diabetic (db/db) group were taken. As shown in
Fig. 1A, a total of 41 miRNAs were altered in the diabetic skeletal mus-
cle as compared to that of the normal mice. Of these, 10 miRNAs were
up-regulated and 31 miRNAs were down-regulated with a p-value
b0.05. Predicted targets of all these altered miRNAs were extracted
from TargetScan, miRanda and PicTar and miRNAs that had targets
predicted by one or more algorithms are shown in Fig. 1B. Only
miR-135a and miR-18a had targets predicted by all the three algo-
rithms. This, however, does not exclude the possibility that the other
miRNAs that did not occupy the common intersection area, could be
of relevance to diabetes. Since prediction algorithms use speciﬁc criteria
for target prediction andmight be prone to generation of false positives,
we followed a common procedure of prioritizing on the miRNAs that
occupy the intersection area to increase the conﬁdence of subsequent
validation and functional relevance [26,27].
We then did a pathway analysis of these common predicted targets
(of miR-135a and miR-18a) using the DAVID and KEGG pathway map-
ping databases. These tools assign signiﬁcant over-representation of
pathways using annotation based enrichment of genes from an input
list versus those that are represented in the whole genome. While
miR-135a targets mapped onto different pathways, those of miR-18a
did not converge onto any common signiﬁcant over-represented path-
way. Importantly, among the pathways overrepresented by the targets
of miR-135a, the type 2 diabetes pathway (corrected p value =
1.20E−04) was the topmost signiﬁcant pathway (Fig. 1C). miR-135a,
therefore, was prioritized for evaluation of a possible role in diabetes.at its targets enrich in. (A) Differentially altered miRNAs in the diabetic mice skeletal
with respect to their levels in the normal mice is represented. Microarray hybridization
o the altered miRNAs as in “A”were extracted from TargetScan, PicTar and miRanda and
mon targets of miR-135a from TargetScan, PicTar and miRanda were classiﬁed into the
0.05) pathways with their values of signiﬁcance are listed. (D) Relative expression of
by quantitative Real Time-PCR. Total RNA (2 μg) from each of the normal and diabetic
the ‘Materials and methods’ section. Values in ‘D’ are means ± SEM of triplicate exper-
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gastrocnemius skeletal muscle and is identiﬁed as a critical regulator
of myogenesis by targeting MEF2C, a transcription factor that actively
regulates several muscle speciﬁc genes [21,28]. We, therefore, further
sought to assess the functional relevance of the elevated levels
of miR-135a in the diabetic gastrocnemius skeletal muscle. The up-
regulated status of miR-135a was validated by quantitative real time
PCR and as in the microarray, miR-135a levels depicted a signiﬁcant
increase in the muscle of db/db mice as compared to normal mice
(Fig. 1D).
As stated above, the pathway term: type 2 diabetes mellitus was
the topmost signiﬁcant pathway overrepresented by the set of com-
mon targets of miR-135a. Although the “type 2 diabetes” pathway re-
fers to diverse converging metabolic pathways, the targets of
miR-135a were majorly enriched amongst the signiﬁcant contributo-
ry pathways of insulin signaling, adipocytokine signaling and pancre-
atic insulin synthesis and secretion (Fig. 2A). Within these, most of
the targets centered on the insulin signaling pathway wherein defects
at one or more points are believed to be strongly associated with in-
sulin resistance and diabetes. IRS2 was one such miR-135a predicted
target that belonged to this pathway. IRS2 occupies a major upstream
position in the insulin signaling pathway, acts as a docking intermedi-
ate between the insulin receptor and other SH2 (src homology) do-
main containing intracellular molecules and its disruption causes
type 2 diabetes [29,30]. These imply that inhibited levels of IRS2
are a major determinant of the diabetic status of an individual
and being a predicted target of miR-135a, the elevated levels of
miR-135a might lead to decreased IRS2 levels. We, therefore, sought
to evaluate whether IRS2 is a validated target of miR-135a and if so,
the physiological relevance of this interaction. The region from 2285Fig. 2. The topmost pathway that the miR-135a targets enrich in and the levels of IRS2 in no
pathway that was most signiﬁcantly over-represented by the miR-135a targets' list. The gr
resentation of the putative miR-135a binding site in the IRS2 3′UTR as in Targetscan. (C) To
and evaluated for IRS2 mRNA levels by quantitative RT-PCR using speciﬁc primers. (D) IRS2
50 μg protein of each sample were resolved by SDS-PAGE, transferred to nitrocellulose me
given and the densitometric analysis is given below. Values are means ± SEM of triplic
(non-diabetic) mice.to 2290 nucleotides on the 3′UTR of IRS2 harbors the binding site
for miR-135a (Fig. 2B) and this corresponds to nucleotide positions
of 23–28 on the mouse IRS2 3′UTR. We therefore, subsequently
assessed the status of IRS2 in the normal and diabetic mice gastrocne-
mius skeletal muscle. As shown in Fig. 2C and D, the levels of IRS2
were signiﬁcantly down-regulated both at the transcript and protein
level in the gastrocnemius skeletal muscle of the db/db mice as com-
pared to those of normal mice, a pattern inverse to that of miR-135a
(Fig. 1D). These indicated that the elevated levels of miR-135a
might be responsible for the decreased levels of IRS2 in the db/db
mice gastrocnemius skeletal muscle.
3.2. miR-135a levels are inhibited in differentiated C2C12 cells and they
regulate IRS2 levels by binding to its 3′UTR
To further validate the miR-135a–IRS2 interaction and to evaluate
the consequences of this miRNA-target pair, we used C2C12 cells that
were differentiated using 0.5% serum containing growth media. Dur-
ing this process of differentiation, undifferentiated myoblast cells that
are mononuclear and fusiform-shaped acquire a multinuclear and tu-
bular phenotype and become more insulin sensitive [31]. To validate
whether miR-135a targets IRS2, we initiated by evaluating the levels
of miR-135a and its predicted target, IRS2 in undifferentiated and dif-
ferentiated C2C12 cells. miR-135a levels were signiﬁcantly reduced in
differentiated C2C12 myotubes (Fig. 3A) together with an increase in
the levels of its putative target, IRS2 (Fig. 3B, D). These suggest that as
C2C12myoblasts differentiate into myotubes, miR-135a levels show a
pattern of down-regulation that might be responsible for the in-
creased levels of its target, IRS2. Since, we had observed an inverse
pattern of expression of miR-135a and IRS2, both in the tissuesrmal and diabetic skeletal muscle. (A) Schematic representation of the Type 2 diabetes
ey shaded boxes with stars represent genes from the list of targets. (B) Schematic rep-
tal RNA (2 μg) from normal and diabetic mice skeletal muscle were reverse transcribed
protein levels were assessed in the normal (N) and diabetic (D) mice skeletal muscle.
mbranes and probed with anti-IRS2 antibody. A representative blot for each animal is
ate experiments from each animal. *p b 0.05 and **p b 0.01 as compared to normal
Fig. 3.miR-135a levels are decreased in differentiated C2C12 cells and they regulate cellular IRS2 levels. (A) C2C12 cells were differentiated into myotubes in the presence of 0.5%
fetal bovine serum. The levels of miR-135a were assessed in these undifferentiated (undiff) and differentiated (diff) cells by quantitative Real-Time PCR using speciﬁc primers as
given in the ‘Materials and methods’ section. (B) C2C12 cells were allowed to differentiate and were transfected with the scramble or miR-135a mimic (100 nM). On termination of
incubation, cells were lysed and 50 μg protein from each incubation was resolved on SDS-PAGE and evaluated for the levels of IRS2 using anti-IRS2 antibody. β-Actin was taken as
the loading control. (C) Differentiated C2C12 cells were transfected with miR-135a mimics at doses of 25–100 nM and incubated for 48 h. On termination of incubation, cells were
lysed and the levels of IRS2 was assessed as in “B”. β-Actin was taken as the loading control. (D) Cells were differentiated and incubated either in the absence or presence of
miR-135a alone or miR-135a and its inhibitor (50 nM). On termination of incubation, cells were assessed for the status of IRS2 by Western Blot analysis. β-actin was taken as
the loading control. C2C12 cells were transfected with miR-135a antagomir (50 and 100 nM) to knockdown endogenous miR-135a levels. After 48 h, the levels of IRS2 mRNA
(E) and protein (F) were assayed by quantitative RT-PCR and Western Blot analysis where 18S rRNA and β-actin were taken as the loading controls, respectively. All experiments
were done thrice and values are means ± SEM of three independent experiments. All blots shown are representatives of the indicated incubations and the densitometric analyses
of the same are given below. *p b 0.05 as compared to undifferentiated cells (A); **p b 0.01 as compared to undifferentiated (undiff) cells and #p b 0.01 as compared to differen-
tiated (diff) cells in the presence of scramble (B); #p b 0.05 and *p b 0.01 as compared to differentiated cells incubated with the scramble (C); **p b 0.01 as compared to undiffer-
entiated cells, #p b 0.05 as compared to differentiated cells with scramble and *p b 0.05 as compared to differentiated cells + miR-135a (D); #p b 0.05 and ##p b 0.01 as compared
to scramble (E and F).
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tiated), we sought to delineate in detail whether IRS2 is functionally
targeted by miR-135a. miR-135a mimics (100 nM) were transfected
in differentiated C2C12 myotubes and as shown in Fig. 3B, miR-135a
signiﬁcantly reduced IRS2 protein expression. Also, incubation of
C2C12 cells with miR-135a mimics from 25 to 100 nM depicted a
dose-dependent decrease in IRS2 levels with the maximum decrease
being evident at 100 nM (Fig. 3C) This decrease at 100 nM was
blunted in the presence of the miR-135a inhibitor (Fig. 3D) sug-
gesting the speciﬁcity of decreased IRS2 protein expression by
miR-135a. To further conﬁrm the speciﬁcity of this miR-135a–IRS2
interaction, we inhibited endogenous miR-135a levels using the
miR-135a inhibitor at two doses of 50 and 100 nM. This was accom-
panied by a dose dependent increase in IRS2 at the transcript and
protein levels (Fig. 3E, F). These results imply towards a speciﬁc inter-
action between miR-135a and IRS2 to regulate endogenous IRS2
levels.
Further, to test whether this decrease in IRS2 levels by miR-135a is
due to miR-135a binding to the 3′UTR of IRS2, we cloned the 3′UTR of
IRS2 into a psiCHECK-2 luciferase reporter vector. HEK cells wereco-transfected with an empty vector or the 3′UTR IRS2 clone together
with either the miR-135a mimic (5–50 nM) or a negative control
(scramble). As compared to the scramble, miR-135a could signiﬁcant-
ly reduce the luciferase activity of the wild type IRS2 3′UTR reporter
vector in a dose dependent manner (Fig. 4A). However, in the pres-
ence of the mutant IRS2 3′UTR reporter, miR-135a did not show any
decrease in the luciferase activity at any of the doses used (Fig. 4A).
Further, the miR-135a inhibitor signiﬁcantly abrogated this decrease
of the wild type IRS2 3′UTR luciferase activity (Fig. 4B) All these sug-
gest that miR-135a decreases IRS2 levels by binding to its 3′UTR.
3.3. miR-135a over-expression attenuates insulin stimulated
phosphorylation and activation of PI3K, Akt and glucose uptake
IRS2 is a critical mediator of the insulin signaling cascade. On
being activated by the insulin receptor, it transmits the activation
signal to downstream signaling mediators, PI3K and Akt that subse-
quently is translated into increased glucose uptake into skeletal mus-
cles. Since we had observed an inhibition in IRS2 levels in the
presence of miR-135a, we further studied the effect of this inhibition
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were transfected with either the negative control (scramble) or
miR-135a mimic, without or with its inhibitor, and then incubated
in the absence or presence of insulin. In the presence of miR-135a, in-
sulin stimulated phosphorylation of PI3Kp85α and Akt were signiﬁ-
cantly reduced (Fig. 5A, B). Also, these decreases were prevented in
the presence of the miR-135a inhibitor. However, under all these
conditions, the total levels of PI3kp85α and Akt were unaltered
suggesting an effect of miR-135a only on insulin mediated phosphor-
ylation of these proteins and not on their total levels.
Since the skeletal muscle is a major tissue responsible for glucose
uptake, we subsequently studied the effects of these events on insulinFig. 4.miR-135a regulates IRS2 levels by binding to its 3′UTR. (A) HEK cells were seed-
ed in 12-well plates and transfected with the vector alone or vector haboring the IRS2
3′UTR (wild type or mutated (mut) cloned in the psiCHECK2 (psiCHK) reporter vector)
together with either the scramble or the miR-135a mimic (5–50 nM). After 48 h, cells
were lysed and the Renilla (RL) and ﬁreﬂy luciferase activities was measured. (B) To
check the speciﬁcity of the miR-135a effect, HEK cells were grown as in (A) and
transfected with the scramble or miR-135a mimic (25 nM) alone or with its inhibitor
(10 nM). Plasmids (150 ng) co-transfected with each of these sets were either the vec-
tor alone or that harboring the wild-type or mutant IRS2-3′UTR. Luciferase activities
were determined as in “A”. All experiments were done in triplicate. Renilla luciferase
values that were normalized to those of ﬁreﬂy luciferase (FL) are expressed as
means ± SEM. *p b 0.05 and **p b 0.01 as compared to cells with scramble
(psiCHK-IRS2 UTR) and #p b 0.05 compared to cells incubated in the presence of
miR-135a (psiCHK-IRS2 UTR + miR-135a).stimulated glucose uptake in C2C12 cells. This was monitored by
measuring the uptake of the glucose analogue, 2-(N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino)-2-deoxy-D-glucose (2-NBDG). While in-
sulin signiﬁcantly stimulated 2-NBDG uptake into C2C12 cells, this
was abrogated by miR-135a (Fig. 5C). The speciﬁcity of this effect of
miR-135a was assessed in the presence of the miR-135a inhibitor
where the inhibitory effect of miR-135a on insulin stimulated glucose
uptake was signiﬁcantly rescued. All these suggest a speciﬁc effect of
miR-135a on insulin signaling and glucose uptake by targeting IRS2.
Finally, in a step towards relating to human subjects, we assessed
the levels of miR-135a in the normal and type 2 diabetic human skel-
etal muscles. As shown in Fig. 5D, miR-135a levels were signiﬁcantly
up-regulated in the skeletal muscle of human type 2 diabetic subjects.
All these results suggest a critical role of the elevated levels of
miR-135a in the diabetic skeletal muscle.
3.4. Silencing of miR-135a in-vivo restores skeletal muscle IRS2 levels
and improves circulatory blood glucose levels
To study the effect of miR-135a silencing in-vivo, we injected ei-
ther the modiﬁed scramble or the miR-135a antagomir to normal
and db/db mice at a dose of 80 mg/kg body weight for three consec-
utive days. As compared to the normal db/+ mice, diabetic db/db
mice had signiﬁcantly higher random glucose levels on each day of
the experiment (Fig. 6A). However, as compared to the db/db mice
injected with the scramble, injection of the miR-135a antagomir in
db/db mice signiﬁcantly decreased the blood glucose levels after the
second dose of injection that further decreased after the third dose
(Fig. 6A). Also, glucose tolerance tests showed an improved glucose
tolerance in db/db mice injected with the miR-135a antagomir as
compared to db/db mice injected with the scramble (Fig. 6B). These
results suggest that miR-135a inhibition in-vivo alleviates hypergly-
cemia and improves glucose tolerance in the db/db mice. Further, in
the gastrocnemius skeletal muscle of db/db mice injected with
miR-135a antagomir, the levels of IRS2 was signiﬁcantly restored
(Fig. 6C). This was also accompanied by signiﬁcant normalization of
the levels p-Akt that lies downstream of IRS2 without any change in
the total Akt levels. It has been suggested that antagomirs delivered
intravenously through the tail vein are targeted to the liver and
since hepatic insulin signaling also contributes to circulatory blood
glucose levels, we also evaluated the status of IRS2, p-Akt and Akt in
the livers of all the three groups of animals. As shown in Fig. 6C, the
levels of IRS2 and p-Akt were signiﬁcantly down-regulated in the
livers of db/db mice. However, unlike the skeletal muscle, the hepatic
IRS2 and p-Akt levels in mice injected with the miR-135a antagomir
were not normalized and they remained comparable to those of
scramble-treated db/db mice (Fig. 6C). Taken together, these data
demonstrate that silencing of miR-135a in-vivo restores IRS2 levels
in the gastrocnemius skeletal muscle of db/db mice and improves
their hyperglycemic status. This improvement in the circulatory glu-
cose levels is due to restoration of skeletal muscle IRS2 levels in the
db/db mice injected with the miR-135a antagomir.
4. Discussion
Although there are several reports that describe the status and
role of miRNAs in diabetic tissues, very few studies have focused on
the diabetic skeletal muscle. The present study sought to evaluate
the miRNA status in the gastrocnemius skeletal muscle of the diabetic
db/db mice and to assess its physiological relevance.
The present data identiﬁed that, of the 41 miRNAs altered in the
diabetic gastrocnemius skeletal muscle, 10 were up-regulated and
31 were down-regulated. Of these, miR-135a was one of the signiﬁ-
cantly up-regulated miRNAs and had targets predicted by TargetScan,
PicTar and miRanda. These targets were signiﬁcantly enriched in
the “type 2 diabetes” pathway with the insulin signaling pathway
Fig. 5. Effect of miR-135a on insulin signaling in C2C12 cells and the status of miR-135a in the normal and diabetic human skeletal muscle. C2C12 cells were allowed to differentiate
and transfected with either the scramble (negative control) or miR-135a mimic (100 nM) or the miR-135a mimic and its inhibitor (50 nM). After 48 h, cells were stimulated with-
out or with insulin (100 nM) for 20 min and on termination of incubation, cells were lysed and lysates (50 μg) were subjected to Western Blot analysis using p-PI3Kp85α and
PI3Kp85α (A) and p-Akt and Akt (B) antibodies. β-Actin was taken as the loading control. Each blot is a representative of three such independent blots and the densitometric
data is given below. (C) To study the effect of miR-135a and its inhibitor on glucose uptake into C2C12 cells, differentiated C2C12 cells were transfected with the scramble or
miR-135a with or without its inhibitor and stimulated with insulin for 10 min. Cells were then treated with insulin and 2-NBDG (500 μM) for 2 h at 37 °C, washed and the
2-NBDG uptake into the cell was evaluated by FACS analysis. (D) To determine the levels of miR-135a in the normal and diabetic human skeletal muscle, 2 μg of total RNA
(n = 3 in each group) from each individual was reverse transcribed and the levels of miR-135a were determined by Real-Time PCR using speciﬁc primers as given in the “Materials
and methods” section. All experiments were done thrice and representative ﬁgures are means ± SEM of three independent experiments. *p b 0.05 as compared to undifferentiated
(undiff) cells in the presence of insulin (A and B); $p b 0.05 and $$p b 0.01 as compared to differentiated cells in the presence of insulin plus scramble; #p b 0.05 as compared to
differentiated (diff) cells in the presence of insulin and miR-135a; *p b 0.01 as compared to control (C); ***p b 0.01 as compared to normal (D).
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list. mir-135a has been reported to be critical in skeletal muscle
myogenesis primarily by regulating the levels of MEF2C [21]. MEF2C
is a transcription factor that activates the expression of several mus-
cle speciﬁc genes [28] and plays a signiﬁcant role in myogenic differ-
entiation [32] and in the maintenance of sarcomere integrity [33].
We, therefore, sought to study in detail, the role of elevated levels
of miR-135a in the gastrocnemius skeletal muscle during diabetes.
Although not in speciﬁc context of diabetes, miR-135a levels have
been reported to be elevated in the inﬂammatory degenerative mus-
cle [22] and to be signiﬁcantly decreased in BMP induced differentiat-
ed osteoblasts [34]. Increased levels of miR-135a have been reported
to increase the activity of caspase 3/7 and promote apoptosis [35].
As stated above, insulin signaling within the “type 2 diabetes”
pathway was signiﬁcantly enriched with genes from the miR-135a
targets' list and here, IRS2 was a physiologically relevant target to be
interested in. It harbors a binding site for miR-135a between 2285
and 2290 nucleotides on its 3′UTR (TargetScan). Here, we provide ev-
idence that miR-135a regulates IRS2 levels by targeting its 3′UTR. IRS2
belongs to the IRS (insulin receptor substrate) family of proteins that
interact with –SH2 domain containing proteins mainly PI3K duringinsulin action [36,37]. Speciﬁcally, IRS2 shares some structural and
functional characteristics with IRS1. There are 22 potential tyrosine
phosphorylation sites in human IRS2 and the presence of a unique re-
gion between 591 and 786 amino acids confers signaling speciﬁcity to
this protein [38]. IRS2 null mice (IRS2−/−), although normal at birth,
show glucose intolerance and insulin resistance that gradually pro-
gresses to hyperglycemia [29,39]. Thesemice exhibit defects inmuscle
glycogen synthesis and impaired insulin action.
Our data show that while miR-135a levels are up-regulated in the
db/db mice gastrocnemius skeletal muscle, IRS2 levels are corre-
spondingly decreased. Using C2C12 myoblast cells, we prove that
miR-135a decreases IRS2 levels by binding to its 3′UTR. The luciferase
activity of the IRS2 3′UTR was signiﬁcantly decreased in the presence
of miR-135a and this decrease was markedly blunted in the presence
of miR-135a inhibitor or in the presence of a mutation in the
miR-135a binding site. To our knowledge, this is the ﬁrst report to
validate IRS2 as a key target of miR-135a.
Activation of IRS2 by binding of insulin to its receptor on the
membrane initiates a signaling cascade that transmits through PI3K
and Akt and subsequently facilitates glucose uptake into the cell
[40]. We, therefore, sought to evaluate the physiological relevance
Fig. 7. Schematic representation of the role of miR-135a on the insulin signaling path-
way. Insulin signaling begins by binding of insulin to its receptor on the membrane
that initiates a cascade of signaling events within the cell. Insulin receptor (IR) phos-
phorylates and activates IRS2 followed by activation of PI3K that converts PIP2 to
PIP3. This then activates a phospholipid dependent kinase, PDK, that regulates the
phosphorylation and activation of Akt. p-Akt then facilitates the movement of Glut4
vesicles to the plasma membrane that promote the uptake of glucose into the cell. In
the presence of miR-135a, IRS2 is inhibited that subsequently stalls the downstream
insulin stimulated signaling events and ﬁnally glucose uptake into the cell is reduced.
IR: Insulin receptor, IRS2: Insulin receptor substrate 2, PI3K: Phosphatidylinositol
3-kinase, PIP2: Phosphoinositide(4,5) bisphosphate, PIP3: Phosphoinositide(3,4,5)tri-
phosphate, PDK: 3-Phosphoinositide-dependent Kinase, Akt: v-Akt murine thymoma
viral oncogene, p-Akt-Phospho-Akt, Glut4: Glucose transporter type 4.
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demonstrate that in the presence of miR-135a, insulin stimulated
PI3K and Akt phosphorylation were signiﬁcantly attenuated. Conse-
quent to these, miR-135a also decreased insulin mediated glucose up-
take into differentiated C2C12 cells. All these effects were abrogated
in the presence of the miR-135a inhibitor indicating towards the
speciﬁcity of these effects of miR-135a. In vivo injection of the
miR-135a antagomir restored skeletal muscle IRS2 levels and also im-
proved the hyperglycemic status of db/db mice. However, in the
livers of db/db mice injected with the miR-135a antagomir, IRS2
and pAkt levels remained as comparable to the scramble-treated
db/db mice liver. Also, in a recent report from our laboratory [18]
regarding hepatic miRNA proﬁling in the same animals, miR-135a
was not altered in the db/db mice liver suggesting that it might not
be contributing to the decreased IRS2 levels in the db/db mice liver.
These suggest that improved hyperglycemia that is observed inFig. 6. Silencing ofmiR-135a in-vivo alleviates hyperglycemia and improves the status IRS2
in the skeletalmuscle. Diabetic db/dbmice (n = 5 in each group)were injectedwith either
the scramble or themiR-135a antagomir (ant-135a) at a dose of 80 mg/kg bodyweight for
three consecutive days. Normal db/+mice (n = 5)were also injectedwith the scramble in
an identicalmanner. (A) Randomblood glucose levels weremeasured onDay 0 (beginning
of the experiment) and on each day of injection. (B) After the third injection, the animals
were fasted overnight and were tested for oral glucose tolerance. (C) Skeletal muscle and
liver tissues were dissected from each animal of all the groups and 50 μg protein was re-
solved through SDS-PAGE and IRS2, pAKT and AKT levels were detected by Western Blot
analysis using speciﬁc antibodies. β-actinwas used as the loading control. A representative
blot is shown and below is the densitometric analysis of the data from 5 animals of each
group. **p b 0.01, ***p b 0.001 as compared to normal db/+ mice. ap b 0.01, bp b 0.05 as
compared to Day 0 in db/db mice injected with ant-135a; $p b 0.01, cp b 0.001 as com-
pared to db/db mice injected with scramble for the same days. *p b 0.05 as compared to
respective time points in db/db animals injected with the scramble. ## p b 0.01 and
#p b 0.05 as compared to normal db/+ mice with scramble and $$p b 0.05 as compared
to the respective proteins in db/db mice + scramble.
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skeletal muscle IRS2 levels.
These results, therefore, provide novel insights into the role that
miRNAs play in diabetes. The identiﬁcation that miR-135a regulates in-
sulin signaling by targeting IRS2 (Fig. 7) unravels one of the mecha-
nisms that might be critical in the pathogenesis of insulin resistance
and diabetes. This new role of miR-135a might open up new avenues
to explore the therapeutic potential of miRNAs. IRS2 is amajor interme-
diate during insulin signaling and its levels and activation are frequently
inhibited in several diabetic species [30,41] and the fact that miR-135a
targets IRS2 identify this miRNA as a novel metabolic regulator.
5. Conclusion
To conclude, the present study demonstrates that miR-135a is one
of the signiﬁcantly up-regulated miRNAs in the gastrocnemius skele-
tal muscle of diabetic db/db mice and by targeting IRS2, it interferes
with insulin signaling and prevents insulin stimulated glucose up-
take. This might contribute to the increased circulating glucose levels
as observed in diabetic subjects. Our study, therefore, provides novel
insights into the understanding of miRNA mediated alterations that
might be critical to the onset and progression of diabetes.
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